Comparing Two Chemo Combos for Advanced Bile Duct Cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced bile duct or gallbladder cancer that cannot be removed by surgery, or it has come back after surgery.
- Your cancer got worse after at least one round of gemcitabine/cisplatin chemo, or you stopped it due to side effects.
- You have not been treated with oxaliplatin or irinotecan before.
- You have not had chemotherapy for advanced bile duct cancer beyond the first line.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy for people whose bile duct cancer has come back after surgery. It tests if a combination of irinotecan liposomes, 5-FU, and leucovorin works better than the standard pill capecitabine.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has worsened after one prior treatment. It may be an option if you haven't taken capecitabine or lenvatinib before and are generally feeling well.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Biliary Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.